Literature DB >> 11732709

Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia.

R Greene1.   

Abstract

NMDA antagonists provide the best pharmacological model of psychosis-related schizophrenia. Data from circuit analysis of the effects of the antagonism of NMDA receptors in the CA1 region of the hippocampus of rats in vitro suggest a hypothesis concerning cortical circuit dysfunction responsible for NMDA antagonist-dependent psychosis, relevant to the psychosis associated with schizophrenia. The NMDA antagonists may act by causing a selective, partial, disinhibition of cortical projection cells. The effects are partially due to the partial role of NMDA-dependent transmission in the excitatory glutamate drive of interneurons. Characterization of the selectivity is incomplete, but includes disinhibition of the recurrent inhibitory circuit and is concentration-sensitive. It may result from differences in NMDA receptors (NMDARs) on interneurons. At higher concentrations, antagonism of all NMDA-dependent transmission results in anesthesia. At low concentration, selective blockade of NMDA-dependent LTP of the recurrent inhibitory circuit may disrupt particular aspects of information processing involving learning and/or memory, consistent with the generation of abnormal associations. An endogenous peptide, NAAG, is shown to antagonize NMDARs in a manner similar to known psychotogenic agents like ketamine or phencyclidine. Finally, mechanisms that could enhance NMDAR function are discussed as possible therapeutic strategies for psychosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732709     DOI: 10.1002/hipo.1072

Source DB:  PubMed          Journal:  Hippocampus        ISSN: 1050-9631            Impact factor:   3.899


  52 in total

Review 1.  GABAergic interneuron origin of schizophrenia pathophysiology.

Authors:  Kazu Nakazawa; Veronika Zsiros; Zhihong Jiang; Kazuhito Nakao; Stefan Kolata; Shuqin Zhang; Juan E Belforte
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

Review 2.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  Ketamine disrupts θ modulation of γ in a computer model of hippocampus.

Authors:  Samuel A Neymotin; Maciej T Lazarewicz; Mohamed Sherif; Diego Contreras; Leif H Finkel; William W Lytton
Journal:  J Neurosci       Date:  2011-08-10       Impact factor: 6.167

Review 4.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

5.  Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine.

Authors:  Shawn E Kotermanski; Jon W Johnson
Journal:  J Neurosci       Date:  2009-03-04       Impact factor: 6.167

Review 6.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

7.  Energization by multiple substrates and calcium challenge reveal dysfunctions in brain mitochondria in a model related to acute psychosis.

Authors:  Jamila Monteiro; Gabriela Assis-de-Lemos; Eduardo de-Souza-Ferreira; Adriana M Marques; Gilda A Neves; Mariana S Silveira; Antonio Galina
Journal:  J Bioenerg Biomembr       Date:  2019-12-18       Impact factor: 2.945

8.  The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia.

Authors:  Ayan Ghoshal; P Jeffrey Conn
Journal:  Future Neurol       Date:  2015

Review 9.  The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia.

Authors:  Samuel M Cohen; Richard W Tsien; Donald C Goff; Michael M Halassa
Journal:  Schizophr Res       Date:  2015-01-09       Impact factor: 4.939

10.  Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.

Authors:  Scott A Schobel; Nashid H Chaudhury; Usman A Khan; Beatriz Paniagua; Martin A Styner; Iris Asllani; Benjamin P Inbar; Cheryl M Corcoran; Jeffrey A Lieberman; Holly Moore; Scott A Small
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.